Aktienanalyse zu Armata Pharmaceuticals, Inc. (ARMP)ARMPArmata Pharmaceuticals, Inc.

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. It is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. It is advancing two lead candidates, such as AP-PA02 and AP-SA02, to address both chronic and acute bacterial infections. Its lead phage candidate, inhaled AP-PA02, focused primarily on the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa. In parallel, it has an acute bacterial infection clinical development plan focused on Staphylococcus aureus bacteremia, a difficult-to-treat and often life-threatening infection. Its AP-PA03 is focused on the treatment of acute ventilator-associated pneumonia. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Currently, Armata Pharmaceuticals Inc (ARMP) is not a good buy. The stock is trading at $2.85, which is significantly down from its 52-week high of $14.98, representing a decline of approximately 81%. Additionally, the Relative Strength Index (RSI) is at 28.706, indicating that the stock is oversold, but this could also suggest continued weakness. The forward P/E ratio is 0, reflecting uncertainty in future earnings, and the company has a gross margin of 100%, but this is overshadowed by substantial losses, including a net income loss of $115.3 million in Q1 2026. The main risk is the high volatility, with a historical volatility of 109.46%.